Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice ; volume:13 ; number:9 ; day:8 ; month:7 ; year:2024 ; pages:2343-2355 ; date:9.2024
Ophthalmology and therapy ; 13, Heft 9 (8.7.2024), 2343-2355, 9.2024
- Creator
-
Debourdeau, Eloi
Beylerian, Helene
Nguyen, Vuong
Barthelmes, Daniel
Gillies, Mark
Gabrielle, Pierre Henry
Vujosevic, Stela
Otoole, Louise
Puzo, Martin
Creuzot-Garcher, Catherine
Wolff, Benjamin
Daien, Vincent
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40123-024-00983-2
- URN
-
urn:nbn:de:101:1-2411111053290.509534161749
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Debourdeau, Eloi
- Beylerian, Helene
- Nguyen, Vuong
- Barthelmes, Daniel
- Gillies, Mark
- Gabrielle, Pierre Henry
- Vujosevic, Stela
- Otoole, Louise
- Puzo, Martin
- Creuzot-Garcher, Catherine
- Wolff, Benjamin
- Daien, Vincent
- SpringerLink (Online service)
Other Objects (12)
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration
Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration
Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration
Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept